Compare Gilead Sciences, Inc. (GILD) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs LYFT Inc — how do they compare? Gilead Sciences, Inc. trades at $133.19 (market cap $163.51B), while LYFT Inc trades at $15.94 (market cap $6.17B). The key difference: Gilead Sciences, Inc. is far larger — about 26.5× LYFT Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| GILD | LYFT | |
|---|---|---|
Market Cap | $163.51B | $6.17B |
Sector | Health | Industrials |
52-Week High | $155.80 | $24.57 |
52-Week Low | $108.22 | $12.65 |
Enterprise Value | $178.05B | $5.71B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lyft trades at $15.61, down 0.38% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $17.86 representing 14% upside. The company shows strong fundamental improvement with 2025 revenue reaching $6.32B and net income of $2.84B, translating to a 43.82% net margin, though recent quarterly earnings have been mixed with two misses in the last three reports. Positive cash flow trends continue with 2025 operating cash flow of $1.17B and net cash flow of $891M.
Lyft presents a compelling value proposition with attractive valuation multiples (P/E of 2.38, P/S of 1.03) and strong profitability metrics, offset by execution risks in autonomous vehicle competition and regulatory scrutiny over pricing practices. The stock offers potential upside to analyst targets but faces challenges in maintaining earnings momentum and navigating competitive pressures from Uber.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
